CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ:SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that Christoph Westphal, M.D., Ph.D., Chief Executive Officer and Vice Chair, will open the NASDAQ stock market on Tuesday, October 16, 2007. Dr. Westphal will be joined by members of the Sirtris management team including Garen Bohlin, Chief Operating Officer, Peter Elliot, Ph.D., SVP Development, Michael Jirousek, Ph.D., SVP Research, Paul Brannelly, VP Finance, Michelle Dipp, M.D., Ph.D., Director of Corporate Development, and David Sinclair, Ph.D., co-founder and member of the Board of Directors of Sirtris.
